Fibromyalgia is a common chronic syndrome defined by core symptoms of widespread pain, fatigue, and sleep disturbance. Other common symptoms include cognitive difficulty, headache, paresthesia, and morning stiffness. F ibromyalgia is a chronic, potentially disabling condition defined by core symptoms of widespread pain, stiffness, fatigue, sleep disturbance, and cognitive dysfunction.
Rather than being a discrete illness, fibromyalgia is considered 1 phenotype of a much larger spectrum of disorders that overlap in individual patients.
There are objective abnormalities of central nervous system neurotransmitters in fibromyalgia. Central nervous system sensitization appears to underlie the widespread clinical features of fibromyalgia and other disorders of central sensitivity syndrome.
In patients with fibromyalgia, tender points are common but are no longer required for the diagnosis of fibromyalgia.
Indiscriminant testing for antinuclear and other autoantibodies should be avoided in the evaluation of a patient with suspected fibromyalgia.
Pain sensitivity in the general population is represented by a bell-shaped curve. Patients with increased pain but few or less prominent other symptoms may be considered to have a degree of "fibromyalgianess" that may respond to therapy usually reserved for fibromyalgia.
Fibromyalgia severity varies widely. Patients with marked tenderness, little depression, and good paincoping skills respond well to treatment and have a favorable prognosis.
Managing fibromyalgia requires a combination of pharmacologic and nonpharmacologic treatment.
A philosophy of "start low, go slow" with exercise and drug therapy improves the likelihood of success in managing fibromyalgia.
with genetic and other susceptibility factors may fail to terminate this transient process, leading to chronic central sensitization.
The evidence for physical trauma as an entry pathway to fibromyalgia has been considered but is controversial, with some studies supporting and others failing to support a relationship. 16, 17 
Psychological Factors and Stress
Depression, anxiety, and difficulty coping with stress are common in patients with fibromyalgia. There is an association between childhood abuse and fibromyalgia- 
Diagnosis
The diagnosis of fibromyalgia as a discrete entity has typically been made using the American College of Rheumatology (ACR) 1990 classification criteria, which is widespread pain for more than 3 months and the presence of at least 11 of 18 tender points. 2 Widespread pain is defined as pain on both sides of the body, pain above and below the waist, and the presence of axial pain. The examiner identifies tender points by using the thumb to exert 4.0 kg pressure (sufficient to blanch the thumbnail)
at each of the discrete tender points to elicit pain.
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The ACR diagnostic criteria were developed for research purposes but were gradually adopted for clinical diagnosis. Using these criteria for diagnosis is problematic for more than 1 reason. Few primary care physicians perform tender point examinations (or correctly perform tender point examinations). 19 The same can be said for many rheumatologists. Fatigue is present in the majority of patients. 1, 2, 19 Poor sleep, with frequent night-time awakenings and difficulty falling back to sleep, is often reported. 10, 19 Exhaustion on awakening may be severe, and morning stiffness is common. "Fibro-fog" describes the symptoms of poor short-term memory and lack of ability to concentrate. 1, 19 Poor balance, dry eyes and mouth, and Raynaud phenomenon are occasionally noted. growing awareness that pain sensitivity in the general population is represented by a bell-shaped curve.
21,22
Many musculoskeletal diseases appear capable of trig- The WPI is calculated by summing up patient reports of pain in 19 separate regions of the body. 1 The SS scale score is calculated by grading several symptoms (eg, pain, fatigue, awaking unrefreshed) on a severity scale from 0 ("no problem") to 3 ("severe, pervasive, continuous, life-disturbing problems").
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Comorbid Conditions
The various members of the CSS family listed in Figure   1 are often referred to as comorbid disorders associated with fibromyalgia, and it is common to find 1 or more of these disorders in patients with fibromyalgia. 
Managing Fibromyalgia
The treatment of patients with fibromyalgia requires a combination of pharmacologic and nonpharmacologic modalities, including exercise and cognitive behavioral therapy.
Nonpharmacologic Management

Patient Education
Simply making a diagnosis of fibromyalgia has a positive effect on its management, leading to a reduction in primary care visits, diagnostic testing, and drug pre- sicca symptoms, or other objective findings. 13 Tests for antinuclear and other autoantibodies have poor predictive value and should be reserved for patients who demonstrate inflammatory or multisystem disease by medical history and physical examination. 13, 27 It is important to emphasize that fibromyalgia may be triggered by and coexist with many chronic diseases. For example, a patient whose rheumatoid arthritis symptoms are well controlled with appropriate therapy but who continues to complain of pain most likely has secondary fibromyalgia and will likely respond to therapy directed toward fibromyalgia.
4,13
Subgrouping Fibromyalgia
There is a wide spectrum of symptom severity in fibromyalgia. Using features of degree of tenderness, depression and anxiety, catastrophizing behavior, and cognitive ability to control pain, investigators identified 3 subgroups of patients with fibromyalgia. 28 The most common patient subgroup (group 1) displayed moderate tenderness, moderate depression and anxiety, moderate tendency to catastrophize, and moderate paincoping skills. The most challenging patient subgroup (group 2) displayed marked tenderness, high depression and anxiety, marked catastrophizing behavior, and poor pain-coping skills. Importantly, a third patient subgroup (group 3) was characterized as having marked tenderness but with little depression/anxiety, little tendency to catastrophize, and good pain-coping skills.
Pharmacologic Management
Fibromyalgia is a syndrome of many symptoms and comorbidities, and there is growing evidence of abnormalities of several neural pathways including those mediated by serotonin, norepinephrine, substance P, and glutamate and other neurotransmitters. It is recommended that TCAs be started at very low doses 2 hours before sleep and titrated upward slowly over several weeks (Table) . 40 Despite their initial effectiveness, the long-term durability of TCAs has been questioned. 40 Anticholinergic effects (dry mouth and constipation), sedation, and grogginess limit their tolerability. Although cyclobenzaprine is classified as a muscle relaxant, it is structurally a TCA. It has been shown to improve sleep, pain, and overall sense of wellbeing but appears to have little or no effect on fatigue in patients with fibromyalgia. There is an emerging and clinically useful concept of considering varying degrees of "fibromyalgianess" in patients avoid excessive combinations of SSRI and SNRI drugs to avoid serotonin syndrome. 42 Features of serotonin syndrome include mental status changes, autonomic hyperactivity, and neuromuscular hyperactivity.
Antiepileptic Drugs
Pregabalin, which is approved by the US Food and Drug
Administration for the management of fibromyalgia, and gabapentin appear to inhibit the release of pain pathway neurotransmitters, including substance P and glutamate. 43 They have been demonstrated to improve pain, sleep, fatigue, and overall quality of life in patients with fibromyalgia. 5,36,43 They are not approved for the management of depression. They are often used as adjunctive therapy, being added to drugs affecting other pain pathways. Adverse effects that limit their use include dizziness, somnolence, and weight gain. 43 These symptoms tend to improve with continued use. Tramadol combined with acetaminophen improves fibromyalgia pain. 33, 36 This drug has mild SNRI effects in addition to mild opioid effects. 5 Care should be taken to 
Other Drugs
Opioids have not been shown to be effective in the management of fibromyalgia and should be avoided if possible. 33, 36 Opioid-induced hyperalgesia and long-term adverse effects limit the usefulness of this drug class. 33, 36 Nonsteroidal anti-inflammatory drugs exert their primary effect on prostaglandin-associated inflammatory pathways and are not very effective in reducing the central pain of fibromyalgia. 36 They are useful, however, in the management of coexisting "pain generators" such as osteoarthritis or degenerative disk disease. 
Conclusion
